ArticlePlastic and reconstructive surgery. Global open2025
Current Practices and Evolving Trends in Implant-based Breast Reconstruction in China: A Nationwide Cross-sectional Survey.
Article in Plastic and reconstructive surgery. Global open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Implant-based breast reconstruction (IBBR) is widely used globally and in China, but regional disparities and concerns about complications persist. This nationwide survey evaluates current IBBR practices and trends. Methods: A cross-sectional survey was conducted in 215 hospitals in 2022, collecting data on surgical volume, reconstruction types, mesh usage, and complications. A total of 198 hospitals provided complete responses, with 122 offering IBBR. Results: IBBR hospitals had higher surgical volumes, greater bed capacity, more breast specialists, and higher reconstruction rates. In these hospitals, IBBR accounted for a median of 93.5% of reconstructions, with a median annual volume of 24.5 (interquartile range [IQR]: 9-59.3). High-volume hospitals (≥100 IBBR/y) performed 69.4% of cases. TiLOOP Bra was available in 76.2% of hospitals, with 45.9% using it in more than 50% of cases. Prepectoral reconstruction comprised a median of 30% of IBBR cases. Most IBBR procedures used a single mesh (median 95%, IQR: 60%-100%), whereas 2-mesh usage was rare. Direct-to-implant reconstruction with mesh was the most common immediate approach (54.1%), increasing from 23.2% in 2017. Radiation therapy (62.3%), capsular contracture (62.3%), and infection (61.5%) were the leading concerns. Estimated median complication rates were 5% (IQR: 0%-10%) for contracture, 3% (IQR: 1%-10%) for infection, and 2% (IQR: 0%-5%) for implant loss. Conclusions: IBBR adoption is increasing in China, particularly with mesh-assisted techniques such as TiLOOP Bra. However, disparities in access and concerns over complications highlight the need for standardized care and further research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.